CN104902883A - 抗焦虑组合物、制剂及使用方法 - Google Patents

抗焦虑组合物、制剂及使用方法 Download PDF

Info

Publication number
CN104902883A
CN104902883A CN201380055487.7A CN201380055487A CN104902883A CN 104902883 A CN104902883 A CN 104902883A CN 201380055487 A CN201380055487 A CN 201380055487A CN 104902883 A CN104902883 A CN 104902883A
Authority
CN
China
Prior art keywords
nmda receptor
receptor antagonist
anxiety
administered
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380055487.7A
Other languages
English (en)
Chinese (zh)
Inventor
斯图亚特·L·韦格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104902883A publication Critical patent/CN104902883A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380055487.7A 2012-08-23 2013-08-23 抗焦虑组合物、制剂及使用方法 Pending CN104902883A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
US61/692380 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
CN104902883A true CN104902883A (zh) 2015-09-09

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055487.7A Pending CN104902883A (zh) 2012-08-23 2013-08-23 抗焦虑组合物、制剂及使用方法

Country Status (11)

Country Link
US (4) US20140057988A1 (enExample)
EP (2) EP3878442A1 (enExample)
JP (2) JP6722453B2 (enExample)
KR (1) KR20150096370A (enExample)
CN (1) CN104902883A (enExample)
AU (1) AU2013305580A1 (enExample)
BR (1) BR112015003796A2 (enExample)
IL (1) IL237340A0 (enExample)
MX (1) MX2015002378A (enExample)
SG (1) SG11201501292UA (enExample)
WO (1) WO2014031975A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111886005A (zh) * 2017-12-15 2020-11-03 法国梅尔基奥材料与生命科学公司 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
EP3498268A1 (en) * 2013-03-15 2019-06-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
SI3297619T1 (sl) * 2015-05-22 2023-02-28 Vistagen Therapeutics, Inc., Terapevtske uporabe L-4-klorokinurenina
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
SG10202012842SA (en) * 2015-09-08 2021-01-28 Childrens Hospital Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
BR112021016404A2 (pt) 2019-02-22 2021-10-13 Harima Chemicals, Incorporated Método de aplicação de material de brasagem sólido, método de produção de peça de trabalho revestida, aparelho de aplicação e material de brasagem sólido de perfil laminado
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
ES2977185T3 (es) * 2019-05-31 2024-08-20 Afyx Dev A/S Administración intranasal de ketamina a pacientes con cefalea en racimos
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
CA2685344A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF A NAESTHESIA: "Patient anxiety scores after low-dose ketamine or fentanyl for epidural catheter placement", 《CANADIAN JOURNAL OF A NAESTHESIA》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111886005A (zh) * 2017-12-15 2020-11-03 法国梅尔基奥材料与生命科学公司 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途
CN111886005B (zh) * 2017-12-15 2023-12-15 瑞斯特医疗公司 氟乙基去甲美金刚胺用于预防和治疗焦虑的用途

Also Published As

Publication number Publication date
MX2015002378A (es) 2015-09-25
JP6771512B2 (ja) 2020-10-21
US20250255834A1 (en) 2025-08-14
US20220160655A1 (en) 2022-05-26
US20180235906A1 (en) 2018-08-23
JP2016501828A (ja) 2016-01-21
EP3878442A1 (en) 2021-09-15
EP2887930A1 (en) 2015-07-01
KR20150096370A (ko) 2015-08-24
JP6722453B2 (ja) 2020-07-15
SG11201501292UA (en) 2015-05-28
EP2887930A4 (en) 2016-03-23
IL237340A0 (en) 2015-04-30
JP2018162302A (ja) 2018-10-18
BR112015003796A2 (pt) 2017-07-04
US20140057988A1 (en) 2014-02-27
WO2014031975A1 (en) 2014-02-27
AU2013305580A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
JP6771512B2 (ja) 抗不安薬組成物、製剤および使用方法
US5543434A (en) Nasal administration of ketamine to manage pain
JP2009530385A (ja) うつ病の治療のためのケタミンの鼻内投与
PT1642578E (pt) Composição de sal de fentanilo para administração nasal
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
US20070066996A1 (en) Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
JP2007505139A (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
Lee et al. Intranasal administration of dexmedetomidine (DEX) as a premedication for pediatric patients undergoing general anesthesia for dental treatment
Arun et al. Comparative study of intranasal dexmedetomidine versus intranasal ketamine as premedicant in children
TW200918048A (en) Drug combinations for the treatment of sialorrhoea
SELBST Managing pain in the pediatric emergency department
JP2016535027A (ja) 非角化重層上皮（ＮＫＳＥ）組織の不快感の治療用局所薬としての１−ジ（ｓｅｃ−ブチル）−ホスフィノイル−ペンタン（ＤＡＰＡ−２−５）
Esmat et al. Comparative study between transdermal nicotine and melatonin patches on postoperative pain relief after laparoscopic cholecystectomy, a double-blind, placebo-controlled trial
Galletly et al. Patient-administered anxiolysis—a pilot study
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
Mohamed et al. Fentanyl versus midazolam as additive to local anesthetic mixture for peribulbar block during posterior segment surgery in adult patients a prospective randomized double-blind study
Jorgensen et al. Premedication in dentistry
Sarhan et al. Analgesic effect of pre-incisional peritonsillar infiltration of ketamine for post-tonsillectomy pain in children
Moayedi et al. Intranasal fentanyl for first-trimester uterine aspiration pain: A randomized controlled trial
TW200824691A (en) Anti-nicotine treatment
Mighri et al. Efficacy of a premedication with melatonin during cataract surgery under peribulbar block: a prospective randomized double-blinded study
Zheng et al. Anesthetic effect of butorphanol tartrate combined with dezocine in hysteroscopic surgery
JP2017538777A (ja) テトラカインをベースにした麻酔剤
Tay et al. Knowing the Emergency Drugs in your Dental Practice

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150909